Recruiting studies: Egfr Sensitive Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06735391 Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06355609 High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-g
Phase 2 · 1 location(s) · Jialei Wang · NCT06652048 A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06945705 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366 Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation
Phase 3 · 2 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07416994 Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05284539 Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Ce
NA · 1 location(s) · Chongqing University Cancer Hospital · NCT06481566 Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Phase 3 · 1 location(s) · Qianfoshan Hospital · NCT06043973 Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
Phase 3 · 2 location(s) · TYK Medicines, Inc · NCT05382728 Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSC
Phase 2 · 1 location(s) · Shandong Public Health Clinical Center · NCT06709859 Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Phase 3 · 3 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT06041776 Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Canc
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07505173 Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06348927

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.